<DOC>
	<DOCNO>NCT00361491</DOCNO>
	<brief_summary>The purpose study evaluate efficacy SSR149415 treatment Major Depressive Disorder , define change baseline visit 7 Hamilton Depression Rating Scale . To evaluate tolerability , safety efficacy disability quality life patient major depressive disorder.To evaluate plasma concentration SSR149415 .</brief_summary>
	<brief_title>An Eight-Week Study Evaluating Efficacy Two Fixed Doses ( 250 mg Twice Daily 100 mg Twice Daily ) SSR149415 Patients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Diagnosis major depressive disorder , recurrent , define Diagnostic Statistical Manual Mental Disorders , 4th edition , Text Revision ( DSMIVTR ) criterion ( 296.3 ) confirm semistructured Mini International Neuropsychiatric Interview ( MINI ) Total score le 24 MADRS . HAMD total score less 18 . Duration current depressive episode less 1 month great 2 year . Patients history presence bipolar disorder psychotic disorder . Patients alcohol dependence abuse substance dependence abuse past 12 month except nicotine caffeine dependence . Patients use follow prior entry Acute Phase : antipsychotic within 3 month , fluoxetine within 1 month , MAOIs within 2 week , antidepressant , moodstabilizer ( lithium , anticonvulsant ) within 1 week . The investigator evaluate whether reason patient may participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Depression</keyword>
	<keyword>antidepressive disorder</keyword>
	<keyword>control clinical trial</keyword>
</DOC>